Study Complete
Sponsor ID
20040156
AIM 3: Anemia and Iron Management with every 3 week dosing in Anemic Subjects with Nonmyeloid Malignancies
Study Details
The study is designed to assess if the addition of intravenous (IV) iron to 500 mcg every 3 week (Q3W) darbepoetin alfa treatment enhances response as compared to the standard practice (oral iron or no iron administration).
Protocol Summary
Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available
Study Documents
Study Synopsis
Available Language(s): English
Locations
No locations found.